Robert W. Holloway, MD
Medical Director (Gyn Onc), Gynecologic Oncologist
Dr. Robert W. Holloway, MD is a board-certified gynecology oncologist in Orlando. Dr. Holloway joined the Florida Hospital Cancer Institute in 1994, and serves as the medical director of the Gynecologic Oncology Program. A graduate of Vanderbilt University School of Medicine, Dr. Holloway completed his OB/GYN residency at the University of Alabama at Birmingham and his fellowship in gynecologic oncology at Georgetown University in Washington, DC. Dr. Holloway is a Fellow of the American College of Surgeons. Additionally, Dr. Holloway is the principal investigator for several clinical trials and lectures regularly both nationally and internationally. His major research interests are robotic surgery and novel ovarian cancer therapies. Surgeons from around the world routinely attend his advanced training programs in robotic surgery.
Multidisciplinary approach to pelvic leiomyomatosis with intracaval and intracardiac extension: A case report and review of the literature
GYNECOLOGIC ONCOLOGY REPORTS
Corrigendum to "A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer" [Gynecologic Oncology 163 (2021) 481-489].
A phase 1b study of intraperitoneal oncolytic viral immunotherapy in platinum-resistant or refractory ovarian cancer
Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety
Neoadjuvant chemotherapy followed by fertility sparing surgery in cervical cancers size 2-4 cm; emerging data and future perspectives
Intratubal Pseudopapillary Histiocytic Hyperplasia: A New Histologic Variant in the Spectrum of Histiocytic Lesions Involving the Fallopian Tube
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
Sentinel lymph node (SLN) isolated tumor cells (ITCs) in otherwise stage I/II endometrioid endometrial cancer: To treat or not to treat?
The gut microbiome and cancer immunotherapeutics: A review of emerging data and implications for future gynecologic cancer research
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Carcinomatosis in Early-Stage Cervical Cancer Treated with Robotic Radical Hysterectomy: Recurrence Patterns, Risk Factors, and Survival
ANNALS OF SURGICAL ONCOLOGY
Education & Training
Vanderbilt University Medical Center
University of Alabama Birmingham
Georgetown University Hospital
American Board of Obstetrics & Gynecology